Podocalyxin-like 1 Antibody (4F10): sc-23903

Podocalyxin-like 1 Antibody (4F10) is a mouse monoclonal IgM kappa light chain antibody raised against human recombinant podocalyxin, effectively detecting podocalyxin-like protein 1 (PODXL) of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry with paraffin-embedded sections (IHCP). PODXL, also known as PCLP1 or PODXL1, is a transmembrane sialomucin characterized by a heavily glycosylated extracellular domain, a single-pass transmembrane region, and a cytoplasmic tail containing multiple phosphorylation sites. The structure of PODXL is crucial for maintaining cell polarity and contributing to the glomerular filtration barrier in kidney podocytes; extensive glycosylation and negative charge help repel adjacent foot processes, preventing their fusion. Structurally related to CD34, PODXL acts as an anti-adhesive molecule, regulating cell-cell and cell-matrix interactions important in vascular development and hematopoiesis. PODXL is expressed in various epithelial tissues, including breast, pancreas, and prostate, in addition to endothelial cells and hemangioblasts. PODXL is involved in cancer progression and metastasis, particularly in breast and prostate cancers, highlighting relevance in oncological research. Anti-PODXL antibody (4F10) recognizes the extracellular domain of PODXL, serving as a valuable tool for studying roles in various biological processes, including inflammation, where PODXL mediates leukocyte adhesion to endothelial cells. PODXL interacts with the actin cytoskeleton via ezrin, which is essential for maintaining cell shape and polarity, and serves as a ligand for L-selectin, facilitating leukocyte rolling on endothelial cells during inflammatory response. PODXL monoclonal antibody (4F10) in non-conjugated form allows versatility in experimental applications, aiding researchers in exploring structural and functional relationships of PODXL in normal physiology and disease states.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Podocalyxin-like 1 Antibody (4F10) References:

1. Podocalyxin-like protein 1 expression is useful to differentiate pancreatic ductal adenocarcinomas from adenocarcinomas of the biliary and gastrointestinal tracts.  |  Ney, JT., et al. 2007. Hum Pathol. 38: 359-64. PMID: 17137615
2. Podocalyxin-like protein 1 expression and correlation with clinical characteristics in epithelial serous and mucinous ovarian carcinoma and tumor-like lesions.  |  Ye, F., et al. 2012. Pathobiology. 79: 307-13. PMID: 22688257
3. Podocalyxin-like protein 1 is a relevant marker for human c-kit(pos) cardiac stem cells.  |  Moscoso, I., et al. 2016. J Tissue Eng Regen Med. 10: 580-90. PMID: 23897803
4. Podocalyxin-like 1 is associated with tumor aggressiveness and metastatic gene expression in human oral squamous cell carcinoma.  |  Lin, CW., et al. 2014. Int J Oncol. 45: 710-8. PMID: 24821609
5. Podocalyxin-like 1 promotes invadopodia formation and metastasis through activation of Rac1/Cdc42/cortactin signaling in breast cancer cells.  |  Lin, CW., et al. 2014. Carcinogenesis. 35: 2425-35. PMID: 24970760
6. Involvement of platelet-tumor cell interaction in immune evasion. Potential role of podocalyxin-like protein 1.  |  Amo, L., et al. 2014. Front Oncol. 4: 245. PMID: 25309871
7. Podocalyxin-like protein 1 functions as an immunomodulatory molecule in breast cancer cells.  |  Amo, L., et al. 2015. Cancer Lett. 368: 26-35. PMID: 26276714
8. Podocalyxin-Like Protein 1 Regulates TAZ Signaling and Stemness Properties in Colon Cancer.  |  Lee, WY., et al. 2017. Int J Mol Sci. 18: PMID: 28946619
9. Podocalyxin-like protein promotes gastric cancer progression through interacting with RUN and FYVE domain containing 1 protein.  |  Zhi, Q., et al. 2019. Cancer Sci. 110: 118-134. PMID: 30407695
10. Podocalyxin-Like Protein 1 Regulates Pluripotency through the Cholesterol Biosynthesis Pathway.  |  Chen, WJ., et al. 2022. Adv Sci (Weinh). 10: e2205451. PMID: 36373710

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Podocalyxin-like 1 Antibody (4F10) has 8 citations in a variety of scientific publications.

Primary antibodies like Anti-Podocalyxin-like 1 Antibody (4F10) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Podocalyxin-like 1 Antibody (4F10) Specifications

Alternate Product Name: PODXL

Product Clone Name: 4F10

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgM kappa light chain

Amino Acids:

Epitope Target: Podocalyxin-like 1

Epitope Species: human

Product Reactivity/Detection: Podocalyxin-like 1

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P)

Vialing Information: Each vial contains 200 µg IgM kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 8 citations in various scientific publications

Available Conjugates/Forms for Podocalyxin-like 1 Antibody (4F10): N/A

The preferred Podocalyxin-like 1 antibody is Podocalyxin-like 1 Antibody (3D3): sc-23904.